inhomogeneous and does not necessarily follow its pseudo-icosahedral outer shape. "However, it isn't as yet clear how reproducible the interior structures of the mimivirus particles are, and this is now under investigation" Claverie says. Details appear in the 3 February 2011 Nature (470: 78 -81) .
"The next experiments are aimed at identifying the complete 3D structure -internal capsid and nucleocapsidof mimivirus at the nanometric scale using higher-intensity photon pulses and improved detectors," say Abergel and Seltzer. "Additionally, several mimivirus genomes will be compared to determine their molecular individualism." "Importantly, the ability to compare the intrinsic variability between seemingly identical biological objects makes it possible to look more deeply into the origin of viruses and their fundamental role in cellular evolution," Claverie says. "X-ray laser imaging of single particles is a brandnew way of looking at biological entities, enabling us to analyze those small inheritable variations from which evolution comes." and Immunity (79:1289 and Immunity (79: -1299 . "Inducing both types of immune system mediators of protection was key, and showed that this approach might be optimal for producing a vaccine against P. aeruginosa," Pier says. Earlier efforts to develop candidate vaccines against this pathogen were based either on molecular components that were purified from cells or on killed but otherwise intact whole cells. The two types of candidate vaccine effectively induced antibodies in the first case or T cells in the second, he says. But neither approach "was comprehensive enough to induce broad-based, effective immunity to P. aeruginosa infection." Moreover, he adds, "Vaccinating humans against P. aeruginosa infections using purified antigens has not shown success to date." Such shortcomings led Pier to suspect that inducing both types of immunity might prove effective. "We reasoned that the lack of success of P. aeruginosa vaccines in humans could be due to the fact that both types of immunity were needed," he says. Further, other findings indicated that, when T-helper type 17 cells are producing the cytokine interleukin-17, antibodies become more effective at killing P. aeruginosa cells in the lungs of infected mice.
Marcia Stone
An additional problem with candidate P. aeruginosa vaccines during the
Probing the Immune System, Enhancing Vaccines, Adjudicating Lawsuits
Recent developments toward understanding the human immune system, enhancing vaccine efficacy, or limiting lawsuits involving commercial vaccines include:
• T-cell receptor diversity "is very large [but] ultimately limited and measureable" and "certain sequences are more favored than others," says Robert Holt of the British Columbia (BC) Cancer Agency in Vancouver and Simon Fraser University in Burnaby, British Columbia, Canada. Based on DNA sequencing to analyze T-cell receptor variants in blood samples, he and his collaborators identified more than 1 million unique sequences. Details appear in the February 24, 2011 Genome Research (doi: 10.1101/gr.115428.110).
• A nanoparticle-based vaccine carrying an influenza viral antigen plus two Toll-like receptor ligands boosts the magnitude and persistence of antibody responses against the influenza virus when tested in rhesus macaques, according to Bali Pulendran at Emory Vaccine Center in Atlanta, Ga., and his collaborators. Details appear in the 24 February 2011 Nature (470:543-547).
• The U.S. Supreme Court in February ruled in favor of vaccine producers, saying that the National Childhood Vaccine Injury Act of 1986 "preempts all design-defect claims against vaccine manufacturers brought by plaintiffs who seek compensation for injury or death caused by vaccine side effects." The lawsuit, Brusewitz v. Wyeth LLC, was brought by a Pennsylvania couple who claimed their daughter became disabled after receiving a diphtheria, tetanus, and pertussis vaccine manufactured by Lederle Laboratories, a company that Wyeth purchased. past 30 years is that, while some antigens worked well individually, they interfered with one another when combined, according to Pier. "We therefore decided to adopt the live, attenuated vaccine approach, as it would make production easier, and would provide a large array of antigens, and induce multiple types of immunity," he says.
The main issue for the combination vaccine is not cost, as the multiple components are relatively inexpensive, but safety, Pier continues. Indeed, unlike the experience with liveattenuated viral vaccines, the success record for live-attenuated bacterial vaccines is not very impressive. Only one of them, the Ty21a strain of Salmonella enterica serovar Typhi, which protects against typhoid fever, is used with any regularity. Although the side effects of that vaccine are mild, there is little other experience to illuminate safety issues with this broad class of bacterial vaccines.
Additionally, in the case of an attenuated vaccine to protect against lung infections from P. aeruginosa, delivery could prove a challenge, particularly if delivering it by inhalation proves necessary for inducing protective immunity, according to Pier. That approach "presents larger safety issues," including, potentially, "an unacceptable level of reactivity-inflammatory responses leading to local pain, discomfort, and more systemic reactions, such as aches, pains, and fever," he says. "We just don't have much experience with this approach in humans." However, the need for a vaccine to protect against P. aeruginosa is acute-and growing, in terms of the numbers of elderly, who are at risk for hospital-acquired infections, and in terms of the frequency of such infections being resistant to available antibiotics, Pier says. "P. aeruginosa is one of the most notorious bacteria manifesting this resistance." Individuals with cystic fibrosis are also especially vulnerable to lung infections caused by this pathogen, points out Gerd Doering of the Institute for Medicine, Microbiology, and Hygiene in Tubingen, Germany. "There is an unmet need for prevention of P. aeruginosa infection in cystic fibrosis and other patients [such as those with severe burns] at risk for P. aeruginosa infection, and Pier's [research] addresses this superbly," he says. "This paper demonstrates conclusively the feasibility of eliciting broad-based immunity against unrelated strains of P. aeruginosa using a live attenuated vaccine," adds Reuben Ramphal of the University of Florida in Gainesville.
David C. Holzman David C. Holzman is the Microbe Journal Highlights Editor

Manganese-Oxidizing Microbes Form Giant Stromatolites in Caves
Manganese-oxidizing microorganisms produce gigantic stromatolites that extend more than 2 km inside the Spanish caves in which they continue to grow, according to a team of Spanish and Australian researchers, led by Carlos Rossi from the University of Madrid in Madrid, Spain. Although other investigators previously reported finding manganese-oxide crusts in caves, the structures they found lacked features consistent with having microbial origins. Details from Rossi and his collaborators appear in the December 1, 2010 Geology (38:1119 -1122 .
Stromatolites, sometimes described as fossilized microbial mats, provide evidence for some of the earliest forms of life on Earth. However, not all stromatolites are fossils, and some are found actively growing. For instance, stromatolites in Shark Bay, Australia, are being formed through the ongoing photosynthesis of cyanobacteria (bluegreen algae) that trap and bind particles such as silt and sand, forming laminated domes of calcium carbonate, CaCO 3 , in shallow marine environments.
"Initially we weren't looking for manganese deposits in this cave," Rossi says. "Since our first visit to El Soplao, it became apparent that the floor of the main gallery of the cave was covered by thick, black manganese deposits, partly covered by sand and mud." Moreover, he and his collaborators did not recognize those
Drop-in Microspheres Extend Light Microscopy Range 20-fold
Inserting transparent microspheres into samples enhances the effective resolution of the light microscope 20-fold, enabling researchers to view objects as small as about 50 nm and extending light microscopy beyond what many experts consider its theoretical limit, according to Lin Li and Zengbo Wang of the University of Manchester in Manchester, England, and their collaborators. "This is a world record in terms of how small an optical microscope can go by direct imaging," Li says. He and his collaborators claim that the new method has "no theoretical limit in the size of features that can be seen." Moreover, unlike electron microscopy, this approach permits use of living cells in aqueous media. The microspheres amplify near-field virtual images that are amplified further by standard optical microscopy. Details appear in the March 2011 Nature Communications (doi:10.1038/ncomms1211).
